Oncology Town Hall™ 2025 ESMO-GI Congress Highlights: The Latest Data on Immune-Based Strategies Across Hepatobiliary Cancers

Overview:

Targeted and immunologic approaches have fundamentally changed the treatment landscape for patients with advanced hepatobiliary cancers. As new treatment approaches are introduced as options in this setting, keeping pace with updates to pivotal trials is of critical importance. In this program, expert faculty in the management of hepatocellular and biliary tract cancers describe key recent clinical trial findings relating to delivery of therapy, coordination of care, and optimal patient selection along the treatment continuum.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Evaluate immune-based treatment strategies for advanced hepatobiliary cancers and their applicability to diverse patient populations, including those with hepatic dysfunction or poor performance status.
• Apply recent evidence to inform treatment selection, sequencing, and delivery of immunotherapy in hepatocellular and biliary tract cancers across frontline and emerging therapeutic settings.
• Evaluate strategies to improve coordination and delivery of care among patients with hepatobiliary cancers

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.